[
  {
    "id": "63-lymph-node-tb-ocr-complete--1--chunk-0",
    "bookId": "63-lymph-node-tb-ocr-complete--1-",
    "sectionTitle": "Topic overview",
    "content": "<!-- Page 1 -->\n\nTB LYMPHADENITIS (LNTB)\n\nDR. BHARATH KATHI MD DNB FIP FACI EDARK\n\n---\n\n<!-- Page 2 -->\n\n\n\n# Topic overview\n\n*   Definition\n*   Epidemiology\n*   Pathogenesis- modes of entry\n*   Symptoms\n*   Signs\n*   Investigations\n*   Treatment\n*   Follow up\n\nDR. BHARATH KATHI MD DNB FIP FADI EDARM\n\n---\n\n<!-- Page 3 -->\n\n\n\n# Introduction\n\n\n## Definition :\n*   Lymph node tuberculosis (LNTB, also called TB lymphadenitis) refers to *M. tuberculosis* infection of the lymph nodes.\n*   As sole manifestation of TB, or alongside pulmonary or miliary TB.\n*   Chest radiograph may show findings in nearly 27.7% of LN TB patients.\n*   Commonest form of extrapulmonary mycobacterial disease (35% of EPTB) - TB lymph node.\n\n---\n\n**Pie Chart Data:**\n\n**Overall TB Classification:**\n*   PTB only (75%)\n*   EPTB only (15%)\n*   Both (5%)\n\n**Breakdown of EPTB:**\n*   LNTB (35%)\n*   Pleural effusion (20%)\n*   Bone and joint (10%)\n*   GUTB (9%)\n*   MTB (8%)\n*   TBM (5%)\n*   ABD (3%)\n*   Others (10%)\n\n---\n\n**Figure 1-** Incidence of EPTB and different organs affected in EPTB.\n*   PTB, pulmonary tuberculosis;\n*   EPTB, extrapulmonary tuberculosis;\n*   GUTB, genitourinary tuberculosis;\n*   MTB, miliary tuberculosis;\n*   TBM, tuberculosis meningitis;\n*   ABD, abdominal tuberculosis;\n*   LNTB, lymph node tuberculosis.\n\n---\n\nDR. BHARATH KATHI MD DNB FIP F...\n\n---\n\n<!-- Page 4 -->\n\n\n\n## Site\n\nMC: **cervical adenopathy** is most common\n(45-75% cases), but inguinal, axillary,\nmesenteric and mediastinal involvement\nMost common cause of mycobacterial\nlymphadenitis caused by- **Mycobacterium tuberculosis [Mtb]** and can also occur due\nto **nontuberculous mycobacteria [NTM]**\n\nDR. BHARATH KATHI MD DNB FIP\nFACI EDARM\n\n---\n\n<!-- Page 5 -->\n\n\n\n# Epidemiology\n\nThe peak age of onset in developed countries has shifted from childhood to ages 20 to 40 years.\n\nIn developing countries where TB is endemic, extrapulmonary TB occurs in up to 60 percent of HIV-infected patients with TB\n\nExtrapulmonary TB cases (including tuberculous lymphadenitis) usually occur among patients with HIV at CD4 counts <300 cells/microL (usually below 100 cells/microL)\n\nDR. BHARATH KATHI MD DNB FIR FACI EDARM\n\n---\n\n<!-- Page 6 -->\n\n\n\n# Pathogenesis\n\n\n\n## Modes of entry of bacilli\n\n\n\n### Via respiratory tract\n*   haematogenous and lymphatic dissemination.\n*   Hilar and mediastinal LN involved initially\n\n\n\n### Via tonsils\n*   Spreads via the lymphatics to the draining cervical lymph nodes.\n    *   **Waldeyer's Tonsillar Ring**\n        *   Lateral pharyngeal band\n        *   Adenoids\n        *   Tubal Tonsil\n        *   Nodules on posterior pharyngeal wall\n        *   Palatine Tonsil\n        *   Lingual Tonsil\n\n\n\n### Via swallowing\n*   occur via swallowing of sputum or milk infected with *M. tuberculosis*/*M. bovis*\n\n---\n\n<!-- Page 7 -->\n\n\n\n# Pathogenesis ; events\n\nEntry & mutliplication $\\rightarrow$ Onset of delayed hypersensitivity (DHR) $\\rightarrow$ Marked hyperaemia, necrosis and caseation $\\rightarrow$ Inflammation, progressive swelling and matting\n\nDR. BHARATH KATHI MD DNB FIP FACI EDARM\n\n---\n\n<!-- Page 8 -->\n\n\n\n# Pathogenesis : events\n\n*   **Adhesion to the adjacent skin, induration and purplish discoloration**\n*   **Centre of the enlarging gland becomes soft and caseous material**\n*   **Rupture into surrounding tissue or through the skin with sinus formation**\n\nDR. BHARATH KATHI MD DNB FIP FACI EDARM\n\n---\n\n<!-- Page 9 -->\n\n\n\n# Jones and Campbell classification\n\n*   **Stage 1-** Enlarged, firm, mobile, discrete nodes showing non-specific reactive hyperplasia (Handwritten: E-FMD)\n*   **Stage 2-** Larger rubbery nodes fixed to surrounding tissue owing to periadenitis (Handwritten: OO, wavy line)\n*   **Stage 3-** Central softening due to caseation necrosis and abscess formation ? Cold abscess\n    *   Cold abscess (not warm) (Handwritten: d/t low grade inflammation)\n*   **Stage 4-** Abscess (rupture) through deep fascia under skin → Collar-stud abscess formation\n*   **Stage 5-** discharging Sinus tract formation\n\n---\n\n**Diagram Stages:**\n\n*   **Stage 1:** Lymphadenitis\n*   **Stage 2:** Matting\n*   **Stage 3:** Cold abscess (Deep to deep fascia)\n*   **Stage 4:** Collar stud abscess (Rupture through deep fascia, the skin, cross-fluctuant, adherent to skin)\n*   **Stage 5:** Sinus formation\n\n---\n\nDR. BHARATH KATHI MD DNB FIP FACI EDARM\n\n---\n\n<!-- Page 10 -->\n\nCold abscess\nSkin\nDeep fascia\nSubcutaneous tissue\nSkin\n\nFig 2.11 Collar stud abscess\n\nSubcutaneous abscess\n\nDue to its proximity to the collar\nbone and its superficial resemblance\nto a collar stud although this is just\none of the five stages of the disease\n\nKATHI MD D.P.H. F.R.C.P. (C)\n\n---\n\n<!-- Page 11 -->\n\n\n\n# Symptoms\n\n*   chronic non-tender lymphadenopathy in a young adult with\n    fever\n*   most commonly in the cervical region\n*   Cough may be a prominent symptom in patients with\n    mediastinal lymphadenopathy\n\nDR. BHARATH KATHI MD DNB FIP\nFACI EDARM\n\n---\n\n<!-- Page 12 -->\n\n\n\n# Examination\n\n*   Palpable lymphadenopathy - varying size, number and consistency\n*   Size of lymph node: Significant if >2 cm diameter in the inguinal region and >1 cm in other regions ⭐\n*   Generalized (>3 groups) - (DID) HIV/NHL/TB/Infectious Mononucleosis/SLE. ✔️✔️✔️✔️✔️\n*   Lymph nodes - discrete or matted, firm or cystic inconsistency if necrosis and abscess formation ✔️\n*   Matted lymph node: Matted lymph nodes are described as a group of nodes that are conglomerated. ✔️ ⭕⭕ 〰️〰️\n*   Not tender unless secondary bacterial infection. ✔️\n\nDR. BHARATH KATHI MD DNB, FIP, FADI, EDARU\n\n---\n\n<!-- Page 13 -->\n\n\n\n# Differential Diagnosis of Lymphadenopathy\n\n*   **Infectious**\n    *   Mycobacterium tuberculosis\n    *   NTM\n    *   Bacterial: sinusitis, otitis externa, cellulitis, abscess, tonsillitis, pharyngitis\n    *   Viral: EBV, CMV, HIV\n    *   Others: fungal, parasitological\n*   Sarcoidosis\n*   SLE\n*   Castleman disease\n*   Histiocytic necrotizing lymphadenitis (Kikuchi-Fujimoto disease)\n*   Drugs\n*   **Neoplasms**\n    *   Primary hematologic malignancy: HL, NHL\n    *   Melanoma, SCC skin cancers\n    *   Solid-organ cancer metastatic\n*   Miscellaneous conditions\n\n---\nDR. BHARATH KATHI MD DNB FIP FACI EDAEM\n\n---\n\n<!-- Page 14 -->\n\n\n\n# WHAT TESTS ?\n\n\n\n## ALL\n*   CXR ✔\n*   HIV Testing ✔\n*   FNAC \\*\n\n\n\n### Superficial lymphadenopathy sample\n*   **Cytopathology** ✔ (by pathologist)\n*   **CBNAAT** (GeneXpert MTB/RIF) ✔\n*   **AFB** ✔\n*   **Culture** (MGIT/LJ media) wherever possible ✔ (microbiology)\n\n\n\n## Selected pts\n*   USG ✔\n*   CT chest & abdomen\n*   Excision biopsy \\*: IF FNAC has been inconclusive, or where malignancy is suspected.\n\nDR. BHARATH KATHI MD DNB (PULMONARY MEDICINE)\n\n---\n\n<!-- Page 15 -->\n\n\n\n# Sampling & Investigations\n\n-   FNA: Direct / Usg guided\n-   Limitations of FNA : <mark style=\"background-color: #D4EDDA;\">Limited sample amount</mark>\n    a.  Tissue morphology might be distorted in immunodeficiency i.e. HIV\n\nDR. BHARATH KATHI MD DNB FIP FACI EDARM\n\n---\n\n<!-- Page 16 -->\n\n\n\n# Sampling & Investigations- Biopsy\n\n(When)\n*   FNA is not diagnostic in the setting of strong clinical suspicion of TB or alternate diagnosis is suspected. => Biopsy\n*   Excisional biopsy >> incisional biopsy (TBEB [Trans Bronchial cryo Biopsy])\n*   Mediastinal lymph node biopsy - mediastinoscopy/VATS\n\n(Handwritten notes around \"Biopsy\" title):\n(HPE)\n-> CBNAAT\n-> AFB\n-> culture\n\n**Merits:**\n*   Highest diagnostic yield / adequacy of sample\n\n**Limitations:**\n*   Requires experience\n*   Local complications like infection, sinus tract formation\n\nDR. BHARATH RATHI MD DNB FIP FACI EDARU\n\n---\n\n<!-- Page 17 -->\n\nFNAC > Biopsy\n(NAAT +ve)\n\nNote: Finding of a caseating granuloma on histopathology with constitutional symptoms is highly suggestive of tuberculosis, ATT may be initiated in such cases even in absence of microbiological evidence\n\nDR. BHARATH KATHI MD DNB FIP FACI EDARM\n36\n\n---\n\n<!-- Page 18 -->\n\n\n\n# Role of radiological imaging in TBLN\n\n*   **USG**: Tuberculous nodes tend to be hypoechoic, round, without echogenic hilus and tend to show intranodal cystic necrosis, nodal matting, and adjacent soft-tissue oedema.\n*   **EBUS**: EBUS-TBNA in whom mediastinal TB is suspected\n    *   *p. D/t tuberculous inflammation*\n*   **CT**: Lymph nodes showing peripheral enhancement with hypodense centres, secondary to caseous and/or liquefactive necrosis. Conglomerate lymph node masses with areas of necrosis secondary to perinodal inflammation.\n*   **MRI**: follow-up cases of mediastinal tuberculosis : mostly hyperintense on T2-weighted images.\n*   During anti-TB treatment, some bacillus-negative tuberculomas do not decrease in size and may even increase, making it difficult for the physician to decide whether to modify treatment.\n*   18F-FDG PET/CT imaging may help, as the changes in glycolytic activity within the inflammatory lesion, measured by 18F-FDG uptake, correlate well with the clinical markers of response\n    *   *\\[X No Metabolic Activity -> It can be dropped]*\n\nDr. Bharath Kadi MD DNB FIR FACI EDARM\n39\n\n---\n\n<!-- Page 19 -->\n\n\n\n# CT\n\nCT provides knowledge of the **site, extent and status** of the affected lymph node\n\n“**RIM SIGN**” that consists of a hypodense centres, representing caseous necrosis, surrounded by a peripheral enhancing rim due to granulomatous inflammatory tissue. (not pathognomonic)\n\nDR. BHARATH KATHI MD DNB FIP FACI EDARM\n\n---\n\n<!-- Page 20 -->",
    "wordCount": 1408,
    "index": 0,
    "subTopicId": "1766794361927-snzifgip"
  },
  {
    "id": "63-lymph-node-tb-ocr-complete--1--chunk-1",
    "bookId": "63-lymph-node-tb-ocr-complete--1-",
    "sectionTitle": "Diagnosis",
    "content": "# Diagnosis",
    "wordCount": 2,
    "index": 1,
    "subTopicId": "1766794361927-emky31f8n"
  },
  {
    "id": "63-lymph-node-tb-ocr-complete--1--chunk-2",
    "bookId": "63-lymph-node-tb-ocr-complete--1-",
    "sectionTitle": "| Bacteriologically Confirmed LNTB case",
    "content": "| Bacteriologically Confirmed LNTB case",
    "wordCount": 5,
    "index": 2,
    "subTopicId": "1766794361927-751ykr7tr"
  },
  {
    "id": "63-lymph-node-tb-ocr-complete--1--chunk-3",
    "bookId": "63-lymph-node-tb-ocr-complete--1-",
    "sectionTitle": "---",
    "content": "---\n\n<!-- Page 21 -->",
    "wordCount": 5,
    "index": 3,
    "subTopicId": "1766794361927-snzifgip"
  },
  {
    "id": "63-lymph-node-tb-ocr-complete--1--chunk-4",
    "bookId": "63-lymph-node-tb-ocr-complete--1-",
    "sectionTitle": "Treatment",
    "content": "# Treatment\n\nLNTB primarily requires medical management, adjunct surgical excision is generally associated with worse outcomes. 6 - ⑨ months\nSix months ATT standard first-line regimen is recommended for peripheral lymph node TB\n\nDR. BHARATH KATHI MD DNB, FIP FACI EDARW\n\n---\n\n<!-- Page 22 -->\n\n\n\n# Assess Response To Treatment At 3- 4 Months\n\n\n\n## Response to therapy at 3 months\n\n*   **Yes**\n    *   Symptom resolution ✓\n    *   Continue ATT ✓\n\n*   **No**\n    *   **Increase in size of LN ± signs of inflammation**\n        *   Check old culture report\n        *   Send new cultures if not available\n        *   Susceptible TB (5)\n            *   Paradoxical worsening (6)\n            *   Refer to higher centre\n        *   Drug resistant TB (8)\n            *   Therapeutic drug monitoring (7) ✓\n                *   *Handwritten note:* sometimes drugs might Not reach to the LN properly [Drugs may Not have properly metabolised & reaching LN]\n            *   Refer to DOTS plus centre (9)\n\n    *   **Constitutional symptoms persist** (a)\n        *   R/o alternate diagnosis (b)\n        *   *Handwritten notes:*\n            *   ? DRTB ✓\n            *   ? Drug related -> TDM ✓\n            *   ? Paradoxical worsening ✓\n            *   ? Alternate diagnosis ✓\n\n---\nBHARATH KATHI MD DNB FIP FACI EDARM\n\n---\n\n<!-- Page 23 -->\n\n\n\n# Treatment\n\n⭐ when to stop ATT in patients with persistently enlarged ⭐ mediastinal lymph nodes ?\n\n✓ when there is absence of interval change in CT/MRI of mediastinal lymph nodes for more than 4 months\n\n✓ with a resolution of all other clinical signs and symptoms.\n\nDR. BHARATH KATHI MD DNB. FIP FACI EDARM\n\n---\n\n<!-- Page 24 -->\n\n\n\n# Residual lymphadenopathy - at the end of treatment\n\n(Handwritten notes: 6m Rx, >1cm size)\n\n*   **Residual lymphadenopathy > 1cm size**\n    *   (Handwritten notes: Inguinal LNs: >2cm? significant, All other LNs: >1cm)\n    *   **If clinical features have persisted or reappeared:**\n        *   Extend 3m Rx (Handwritten, circled)\n        *   Addnl 3 months of RHE\n        *   Followed by BIOPSY & culture (Handwritten: sensitivities)\n    *   **If clinical features have resolved:**\n        *   Residual fibrotic LN\n        *   NO NEED TO EXTEND ATT\n\n---\nDR. BHARATH KATHI MD DNB FIP FAGI EDARM\n\n---\n\n<!-- Page 25 -->\n\n\n\n# Paradoxical Reaction\n\n*   Patient on ATT\n*   Initial Improvement\n*   Clinical or radiological worsening of pre-existing lesions / new lesions are developed (Handwritten: lesions)\n*   first 3 weeks to 4 months may be due- Paradoxical Reaction (Handwritten: worsening due to immune system)\n\nself-limiting, serious morbidity and, on rare occasions, death\n\nDR. BHARATH KATHI MD DNB FIP FACI EDARM\n45\n\n---\n\n<!-- Page 26 -->\n\n\n\n# Paradoxical Reaction\n\n*   Rule out alternative diagnosis\n\nManagement:\n*   Continuation of ATT\n*   Symptomatic treatment\n*   NSAIDs for pain\n*   USG guided aspiration in fluctuation For biopsy & culture\n\n*Handwritten notes:*\nIf you are strongly suspecting something else\n↓ an ORTB Alternate cause\n\n---\n\n<!-- Page 27 -->\n\n\n\n## Follow up\n1, 2, 3-4 and 6 months.\nImaging to be repeated if clinically indicated.\n\nDR. BHARATH KATHI MD DNB FIP FACI EDARM\n\n---\n\n<!-- Page 28 -->\n\n\n\n# Treatment ; EVENTS\n\nI. The appearance of new lymphadenopathy during RX or Enlargement of the existing nodes :\n* paradoxical response? ✔ → If yes → wait & watch | symptomatic Mxl\n* Superadded infection? ✔ [High grade fever, local rise of temperature, fluctuant +ve]\n* Nontuberculous mycobacterial infection ?? [Like initially it was AFB +ve & NAAT -ve, But was thought on MTB]\n* Alternative diagnosis e.g., malignancy, Kikuchi-Fujimoto, Kimura lymphadenitis Kikuchi-Fujimoto, Kimura lymphadenitis\n* Treatment failure or Decreased compliance issues / Poor absorption, Poor drug penetration into the lymph node/absorption\n* Drug resistance (INH mono-resistance/MDR TB)\n\nDR. BHARATH KATHI MD DNB FIP FACI EQARM\n\n---\n\n<!-- Page 29 -->\n\nDr Bharath Kanthi\n\nI. **Development of fluctuation**: <u>aspiration</u>, if Secondary bacterial infection - [TEXT OBSCURED]\n\nII. **Sinus tracts formation**: [TEXT OBSCURED]\n    [TEXT OBSCURED]\n    [TEXT OBSCURED] → cosmetic reason✓\n\nIV. **Non-healing sinus tracts** - [TEXT OBSCURED]✓\n\nV. **Residual lymphadenopathy** after completion of treatment\n    * Symptoms ⊕\n        * ↓ 3m✓\n    * Symptoms ⊖\n        * ↓ Fibrotic LNV✓\n\nDR. BHARATH KATHI MD DNB FIP FACI EDARM\n50\n\n---",
    "wordCount": 665,
    "index": 4,
    "subTopicId": "1766794361927-snzifgip"
  }
]